Joseph Geraci
Chief Tech/Sci/R&D Officer chez NETRAMARK HOLDINGS INC.
Fortune : 932 535 $ au 31/03/2024
Profil
Joseph Geraci is the founder of NetraMark Corp., which was founded in 2016.
He holds the title of Chief Executive Officer at NetraMark Corp.
Dr. Geraci's current job is as a Director, Chief Scientific & Technology Officer at NetraMark Holdings, Inc. Dr. Geraci's former job was as the Chief Scientific Officer at Open Source Health, Inc. Dr. Geraci has a doctorate degree from the University of Southern California and graduate and doctorate degrees from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NETRAMARK HOLDINGS INC
6,01% | 28/03/2024 | 4 002 298 ( 6,01% ) | 932 535 $ | 31/03/2024 |
Postes actifs de Joseph Geraci
| Sociétés | Poste | Début |
|---|---|---|
| NETRAMARK HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 18/10/2021 |
NetraMark Corp.
 NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Chief Executive Officer | 01/01/2016 |
Anciens postes connus de Joseph Geraci
| Sociétés | Poste | Fin |
|---|---|---|
Open Source Health, Inc.
 Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Chief Tech/Sci/R&D Officer | - |
Formation de Joseph Geraci
| University of Southern California | Doctorate Degree |
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NETRAMARK HOLDINGS INC. | Technology Services |
| Entreprise privées | 2 |
|---|---|
Open Source Health, Inc.
Open Source Health, Inc. Financial ConglomeratesFinance Open Source Health, Inc. operates as a capital pool company. The company was founded by Sonya Satveit and is headquartered in Calgary, Canada. | Finance |
NetraMark Corp.
NetraMark Corp. Information Technology ServicesTechnology Services Part of NetraMark Holdings, Inc., NetraMark Corp. is an AI and pharma-tech company based in Toronto, CA. NetraMark was acquired by NetraMark Holdings, Inc. on October 18, 2021 for $11.92 million. The private company focuses on developing AI/ML solutions for the pharmaceutical industry, using a novel topology-based algorithm to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. NetraMark's proprietary next-generation AI solutions for pharmaceutical and biotechnology companies allow them to leverage small to large data sets in order to prevent clinical trial failure, identify biomarkers, implement adaptive trials, accelerate drug discovery, and enable drug repurposing and resurrection. The Canadian company was founded in 2016 by Joseph Geraci and Richard Brooks, with Joseph Geraci serving as CEO since then. | Technology Services |
